The three major varieties are out, and the top 10 best-selling drugs in 2022 will undergo great changes!

Market analysts try every year to predict which drugs will be the "blockbusters" and the most "gold", often highlighting the biggest trends in biopharmaceutical R&D
.
2022 is no exception.
Evaluate Pharma, a world-renowned pharmaceutical market research organization, recently made predictions on the 10 best-selling drugs this year.
The total global sales of these drugs is expected to exceed 100 billion US dollars
.
It is worth noting that although the new crown epidemic has fundamentally changed the definition of "blockbuster", two mRNA vaccines from Pfizer/BioNTech and Moderna respectively occupy the first or third place, but the fields of cancer and autoimmune diseases are still spawned.
The fertile ground for the best-selling drug, the "King of Medicine" Humira may win the runner-up with US$21.
158 billion, while the anti-tumor star drug Kreida has further narrowed the gap with Humira
.
Compared with the best-selling list predicted last year, the drugs on the list are "in and out"
.
The biological targeting agent Dabitux may rank among the top 10 best-selling drugs in the world for the first time this year with a gratifying sales growth rate, while the anticoagulants Xarelto/Xarelto (rivaroxaban) and small molecules, which were at the bottom last year The BTK inhibitor Yike/Imbruvica (ibrutinib) and the ophthalmic biologic drug Aliya/Eylea (aflibercept), which are about to be impacted by biosimilars, were tragically eliminated
.
In 2022, the world's top 10 best-selling drugs, the "King of Medicine", Humira, the vaccine product "Drug King", gave way ahead of schedule The long-standing title of "Drug King" has given way to Pfizer/BioNTech's mRNA vaccine, but it still cannot change the fact that it is one of the best-selling drugs in pharmaceutical history
.
According to data, from the approval of listing in 2003 to the end of June 2020, Humira has brought AbbVie a total of 165.
8 billion US dollars in revenue
.
In the first three quarters of 2021, Humira contributed $15.
36 billion to AbbVie's performance
.
This year, Humira may continue to generate more than $20 billion in global sales for AbbVie, but because its key patents will officially expire in 2023, the competitive barriers built over the years are about to collapse.
The last spree before the blockbuster drug goes to the "patent cliff"
.
According to the first Humira biosimilar patent settlement agreement signed by AbbVie and Amgen, the latter will be the first to launch Humira biosimilars in the U.
S.
market in January 2023, while other pharmaceutical companies such as Boehringer Ingelheim Shang's biosimilars will also be launched at different times of the year, which will bring the once impeccable Humira into a siege
.
Although the legendary road of Humira's "Drug King" may slowly come to an end, the development of the autoimmune disease market continues
.
With the gradual deepening of the research on the disease mechanism, interleukin inhibitors have begun to shine in a variety of autoimmune diseases.
It can be seen that the IL-4/13 inhibitor Dabitux has both entered the top ten best-selling list
.
As can be seen from the 2021 annual report released by Johnson & Johnson recently, although Remicade (infliximab) was hit by biosimilars in the U.
S.
market, sales continued to decline from a peak of $7 billion to $3.
19 billion, but with the built-in With the steady growth of the three product portfolios of Tenoa/Tremfya (guselkumab), Starno, and Simponi/Simponi (golimumab), the self-immunity field remains its top disease area in terms of total revenue
.
Among them, Starno led with a dazzling performance of 9.
134 billion US dollars, a year-on-year increase of 18.
5%.
It may be just around the corner to break the predicted 10 billion mark this year
.
In addition, Johnson & Johnson also plans to submit a variety of self-immunity drugs including bermekimab, JNJ-2113, nipocalimab and other listing applications in the next few years, and continue to consolidate its leading position in the self-immunity track.

.
Dabitux, jointly developed by Sanofi and Regeneron, has successfully tapped the market potential of atopic dermatitis (AD).
As a monoclonal antibody drug targeting IL-4R, Type 2 immune-related inflammatory diseases are well controlled, making this blockbuster drug an ace in Sanofi's autoimmune pipeline
.
In another "2022 Global Top Ten Fastest Growing Drugs" list released by evaluate Pharma, Dabitux ranked third, second only to Merck's flagship product Ke Ruida
.
However, as two JAK inhibitors, Pfizer's Cibinqo (abrocitinib) and AbbVie's Rinvoq (upadacitinib), have been approved in succession at the beginning of this year, they will compete head-to-head with Dabitux in the segmented field.
The competitive pressure cannot be ignored
.
The gap between OK drugs further widens BMS’s entry into the list with three drugs to become the biggest winner.
Although the epidemic of the century has made the two mRNA vaccines “airborne” directly to the top of the best-selling drug list, analysts generally believe that this may only be a short-term sales boom.
After the pandemic is over, sales of related vaccine products are forecast to decline rapidly, and the new successor to the "Drug King" still has to rely on Merck's blockbuster drug Kreida (K drug) in the anti-tumor field
.
The rise in the ranking of K drugs was also affected by mRNA vaccines.
The sales of this PD-1 inhibitor have been second only to Humira in the past few years, and have now been pushed to tie for third place
.
Before the start of the new crown pandemic, analysts believed that as the deserving king of the PD-1/L1 inhibitor class, K drug was expected to surpass Humira in 2024
.
In the first three quarters of 2021, K medicine generated US$12.
609 billion in revenue for Merck, which is still a US$2.
7 billion gap compared to Humira
.
However, before falling off the "patent cliff" in 2028, there is still plenty of time to tap the huge clinical application potential of K medicine
.
At this stage, all immune checkpoint inhibitors continue their impressive expansion of new indications and treatment lines
.
At present, K drug has nearly 40 indications, including the approval at the end of last year as an adjuvant therapy for renal cell carcinoma, etc.
In addition, the recently disclosed phase III positive data of monotherapy for advanced liver cancer consolidates the good news such as second-line treatment indications for liver cancer.
, will help the K drug achieve its sales forecast of nearly $19.
5 billion this year
.
The success of Drug K in approved indications will further widen the gap between it and direct competitor Bristol-Myers Squibb (BMS) Opdivo (Drug O), which has almost twice as many approved indications as the latter.
times as much
.
According to forecasts, the sales of O drugs this year are less than half of those of K drugs
.
However, as can be seen from the sales of O Medicine in the first three quarters of 2021 of US$7.
922 billion, BMS seems to be gaining momentum
.
Analysts pointed out that the recent success of O-drug combined with chemotherapy in the first-line treatment of gastric cancer may help boost future sales
.
However, BMS is still the biggest winner of the best-selling drug forecast.
In addition to O drug on the list, the anticoagulant drug Aleto, co-developed with Pfizer, and the blockbuster hematological tumor product REVLIMID obtained from the acquisition of Celgene are also impressively listed.
column
.
As a blockbuster drug for multiple myeloma, REVLIMID may only be dwarfed by two drugs, Humira and K-Drug
.
In the first three quarters of 2021, REVLIM contributed US$9.
493 billion in performance to BMS, a veritable "cash cow"
.
But REVLIMID's time in the spotlight is fading fast, and its generics will debut this year
.
Although evaluate Pharma has given REVLIMID's growth forecast this time, BMS has recently revealed that the drug's sales are expected to eventually fall between $9.
5 billion and $10 billion, which is obviously lower than analysts' expectations
.
At the 2022 JP Morgan Conference, BMS also pointed out that its next-generation immunomodulatory drug iberdomide, which is under development, will replace REVLIMID as the basis for first-line multiple myeloma treatment.

.
The three best-selling drugs in the past have been eliminated, and the biosimilar drugs have reshaped the market structure
.
Although the two major anticoagulant drugs Xilito and Aleto have a competitive relationship, they were both able to enter the top ten best-selling drugs last year, which caused heated discussions in the industry at that time
.
But in this year's list, Xilito, who was already at the bottom, fell out of the industry's field of vision without any surprise
.
Xarito, which is jointly developed with Johnson & Johnson, is Bayer's highest-selling drug, with global sales reaching US$7.
5 billion in 2020 and still receiving US$5.
236 billion in the first three quarters of 2021
.
However, unlike Aleto, which won a patent in the United States, it will delay its generic drugs entering the market until 2026.
The patent of Xilito has expired in China in 2020, and will be launched in the European Union, the United States, and Japan in 2023-2025.
Wait for the country or region to expire
.
In the fifth batch of national procurement, more than 20 pharmaceutical companies competed for rivaroxaban to become the product with the largest decline, and the price per tablet was as low as 0.
16 yuan.
Bayer, the original research pharmaceutical company, was not selected
.
Also facing the challenge of the "patent cliff" is the ophthalmic biological drug Eylea (Aflibercept) jointly developed by Regeneron and Bayer, which also made it disappear directly from the fifth best-selling forecast last year.
in the list
.
Aflibercept, ranibizumab, and conbercept are considered to be three classic VEGF inhibitors for the treatment of ocular fundus diseases.
Its global sales in 2020 will reach US$7.
909 billion, and the sales in the first three quarters of 2021 will still be $6.
904 billion
.
Like Xarelto, Aaliyah's patent has expired in China in 2020, and the patent in EU countries will also expire in 2025
.
As the patent period approaches, foreign companies such as Samsung Bioepis, Sandoz, and Amgen in South Korea, as well as local pharmaceutical companies such as Innovent and Occidental, are accelerating the clinical progress of aflibercept biosimilars
.
Yike/Imbruvica (ibrutinib), jointly developed by AbbVie and Johnson & Johnson, is the world's first BTK inhibitor, which has better efficacy in the treatment of BTK-dependent B-cell malignancies
.
Yike's absence from the best-selling list is a little surprising, because it is regarded by the industry as the only seed player under AbbVie that has the strength to replace Humira.
Its global sales in 2020 will be $9.
442 billion, and the first three quarters of 2021 will also Recorded a performance of 7.
370 billion US dollars
.
Although the current ibrutinib market is still dominated by two original research companies, as the core patent will expire around 2026, domestic companies developing ibrutinib generic drugs quickly follow up, Simcere Pharmaceuticals, Chia Tai Tianqing , Hisun Pharmaceutical, Shanghai Huilun and other local pharmaceutical companies are among them
.
In addition, the second generation of BTK drugs such as Merck, Gilead and Roche are working hard to solve the drug resistance problem of the first generation, and it is expected to have a greater impact on the sales of Yike after the listing
.
For the variety change of the best-selling drug list in the future, further feedback from the pharmaceutical market is required
.
However, the new crown pandemic tells the industry that some products can become "blockbusters" in just one year.
Judging from the "myth" created by mRNA vaccines, next year's global best-selling drugs list may appear new crown-related oral drugs Antiviral drugs
.